Ecnoglutide

Ecnoglutide (XW003; CAS 2459531-73-6; molecular formula C194H304N48O61; molecular weight 4284.84 g/mol) is a lipopeptide analog of human glucagon-like peptide-1 (GLP-1) (7-37) engineered with an alanine-to-valine substitution at position 8 and a C18 fatty diacid conjugated to the epsilon-amino group of lysine 30 through a gamma-glutamate and dual 2-(2-(2-aminoethoxy)ethoxy)acetic acid linker. Designed and developed at Sciwind Biosciences (Hangzhou, China), ecnoglutide is the first GLP-1 receptor agonist intentionally optimized for cAMP signaling bias: it activates the Gs/adenylyl cyclase/cAMP cascade with an EC50 of 0.018 nM (comparable to semaglutide at 0.012 nM) while producing substantially reduced beta-arrestin recruitment (Emax approximately 54 to 60 percent of semaglutide, EC50 approximately 1300 nM) and negligible GLP-1 receptor internalization (EC50 greater than 10 micromolar versus 0.093 micromolar for semaglutide) [1]. The biased signaling profile preserves receptor surface density and downstream insulin secretion while reducing the desensitization, tachyphylaxis, and gastrointestinal adverse events theoretically attributable to beta-arrestin-mediated receptor endocytosis. In surface plasmon resonance binding studies, ecnoglutide demonstrates a dissociation constant (KD) of 1.45 nanomolar at the human GLP-1 receptor, approximately 10- to 30-fold higher affinity than semaglutide (KD 17.0 nanomolar) [1]. The compound consists exclusively of natural amino acids, simplifying the manufacturing process relative to semaglutide (which incorporates alpha-aminoisobutyric acid at position 8). Pharmacokinetics in healthy human volunteers support subcutaneous dosing: the terminal elimination half-life at steady state ranges from 124 to 138 hours, with median time to peak concentration (Tmax) of 12 to 72 hours and dose-proportional plasma exposure across the studied dose range [1]. In the Phase 2 randomized, double-blind, placebo-controlled trial in 145 adults with type 2 diabetes, ecnoglutide at 0.4, 0.8, and 1.2 mg for 20 weeks produced HbA1c reductions of 1.81, 1.90, and 2.39 percentage points, respectively, versus 0.55 points on placebo [2]. In the Phase 3 EECOH-1 trial of ecnoglutide monotherapy (0.6 mg and 1.2 mg) in 211 patients with type 2 diabetes, up to 76.1 percent of patients in the 1.2 mg cohort achieved HbA1c targets of 6.5 percent or less [3]. In the Phase 3 EECOH-2 active-comparator trial, ecnoglutide 0.6 mg and 1.2 mg demonstrated non-inferiority to dulaglutide 1.5 mg on HbA1c reduction over 52 weeks, with the 1.2 mg dose achieving statistically significantly greater reduction [4]. In the Phase 3 SLIMMER trial in 664 adults with overweight or obesity without diabetes, ecnoglutide at 1.2, 1.8, and 2.4 mg produced mean body weight reductions of 9.1, 10.9, and 13.2 percent, respectively, at 40 weeks versus 0.1 percent on placebo; at 48 weeks, the 2.4 mg dose achieved 15.4 percent mean weight loss, with 92.8 percent of participants achieving 5 percent or greater weight loss [5]. The safety profile is consistent with the GLP-1 receptor agonist class: the principal adverse events are gastrointestinal (nausea, diarrhea, decreased appetite), predominantly mild to moderate in severity, concentrated during the dose-escalation period, and diminishing over time. Hypoglycemia risk is low. China's National Medical Products Administration (NMPA) approved ecnoglutide injection for chronic weight management in January 2026, making it the first approved cAMP-biased GLP-1 receptor agonist worldwide [6]. The compound is not approved by the United States Food and Drug Administration or by the European Medicines Agency as of the most recent monograph revision. This monograph reviews the chemistry, biased-agonist pharmacology, comprehensive pharmacokinetics, the clinical evidence base across type 2 diabetes and obesity indications, sourcing and quality considerations, reconstitution and handling, stack-interaction implications, adverse-event signal, and a comparative assessment of five GLP-1 receptor agonist and incretin mimetic candidates against ecnoglutide on five competency standards.